These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7726705

  • 21. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Kornegay S.
    N Engl J Med; 1994 Mar 10; 330(10):657-62. PubMed ID: 7906384
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM.
    JAMA; 1998 Mar 25; 279(12):930-7. PubMed ID: 9544767
    [Abstract] [Full Text] [Related]

  • 27. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group.
    Gerstoft J, Melander H, Bruun JN, Pedersen C, Głtzsche PC, Berglund O, Mathiesen L, Skinhłj P, Norrby SR.
    Scand J Infect Dis; 1997 Mar 25; 29(2):121-8. PubMed ID: 9181646
    [Abstract] [Full Text] [Related]

  • 28. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG.
    Ann Intern Med; 1995 Jan 01; 122(1):24-32. PubMed ID: 7985892
    [Abstract] [Full Text] [Related]

  • 29. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
    Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, Wyvill KM, Steinberg SM, Agbaria R, Mitsuya H.
    J Infect Dis; 1994 Jan 01; 169(1):9-17. PubMed ID: 7903976
    [Abstract] [Full Text] [Related]

  • 30. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS, DeMasi R, Hill AM.
    AIDS; 1998 Mar 26; 12(5):F23-8. PubMed ID: 9543436
    [Abstract] [Full Text] [Related]

  • 31. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov 26; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 32. Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
    Baldeweg T, Catalan J, Gazzard BG.
    J Neurol Neurosurg Psychiatry; 1998 Jul 26; 65(1):34-41. PubMed ID: 9667558
    [Abstract] [Full Text] [Related]

  • 33. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
    Katzenstein DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S, ACTG 302 Study Team.
    AIDS Res Hum Retroviruses; 2001 Feb 10; 17(3):203-10. PubMed ID: 11177402
    [Abstract] [Full Text] [Related]

  • 34. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA, Barr MR, McIntyre KI, Thornton JR, Shay WM, Feldman RD, George NJ, Britton DJ.
    Int J STD AIDS; 1995 Feb 10; 6(1):19-26. PubMed ID: 7727578
    [Abstract] [Full Text] [Related]

  • 35. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
    Raboud JM, Montaner JS, Rae S, Kahn J, Hammer SM, Katzenstein DA, Pavia A, Dolin R, Hughes MD, Cross A, Beltangady M, Gatell J, Dunkle L, Smaldone L.
    Antivir Ther; 1997 Dec 10; 2(4):237-47. PubMed ID: 11327443
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.
    J Infect Dis; 1996 Jun 10; 173(6):1354-66. PubMed ID: 8648207
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC.
    Ann Intern Med; 1994 Aug 15; 121(4):263-8. PubMed ID: 7518658
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.